Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup

Lancet

Volumn 350, Issue 9082, 1997, Pages 911-917

  Souhami, Robert L ^a   Craft, Alan W ^b   Van Der Eijken, Jan W ^c   Nooij, Marianne ^d   Spooner, David ^e   Bramwell, Vivien H C ^f   Wierzbicki, Rafal ⁱ   Malcolm, Archibald J ^b   Kirkpatrick, Anne ^g   Uscinska, Barbara M ^h   Van Glabbeke, Martine ^g   Machin, David ^h  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g EORTC DATA CENTER   (Belgium)

^h MEDICAL RESEARCH COUNCIL   (United Kingdom)

ⁱ Admin ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ADULT; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEARING LOSS; HEART ARRHYTHMIA; HISTOPATHOLOGY; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OSTEOSARCOMA; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN DISEASE; THROMBOCYTOPENIA; VOMITING;

EID: 0031588180     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)02307-6     Document Type: Article

References (17)

1. 1 Eilber F Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomised prospective trial. J Clin Oncol 1987; 5: 21-26.
2. 2 Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 1600-06.
3. 3 Bramwell VHC, Burgers M, Sneath R, et al. A comparison of two short intensive chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992; 10: 1579-91.
4. 4 Winkler K, Beron G, Salzer-Kuntschik M, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 1984; 2: 617-24.
5. 5 Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-30.
6. 6 Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10: 5-15.
7. 7 Lange B, Levine AS. Is it ethical not to conduct a prospectively controlled trial of adjuvant chemotherapy in osteosarcoma. Cancer Treat Rep 1982; 66: 1699-703.
8. 8 Rosen G, Nirenberg A. Chemotherapy for osteosarcoma; an investigative method, not a recipe. Cancer Treat Rep 1982; 66: 1687-97.
9. 9 Provisor AJE, Hinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997; 15: 76-84.
10. 10 Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329-37.
11. 11 Grem JL, King SA, Wittes RE, Leyland-Jones B. The role of methotrexate in osteosarcoma. J Natl Cancer Inst 1988; 80: 626-56.
12. 12 Graf N, Winkler K, Betlemovic, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osterosarcoma. J Clin Oncol 1994; 12: 1443-51.
13. 13 Delepine N, Delepine G, Bacci G, et al. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Cancer 1996; 78: 2127-35.
14. 14 Smith MA, Ungerleider RS, Horowirz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991; 83: 1460-70.
15. 15 Ornadel D, Souhami RL, Whelan J, et al. Two-weekly doxorubicin and cisplatin with granulocyte colony stimulating factor as an adjuvant chemotherapy for osteosarcoma: a phase II trial of the European Osteosarcoma Intergroup. J Clin Oncol 1994; 12: 1842-47.
16. 16 European Osteosarcoma Intergroup. A randomised trial of chemotherapy with or without granulocyte colony: stimulating factor in operable osteosarcoma. Protocol: EORTC 80931: Brussels, Belgium; and MRC BO06: Cambridge, UK, 1993.
17. 17 Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987; 5: 1191-98.